ViGenCell wins ASCO oral slot with Phase 2 cell therapy data

ViGenCell has been selected to deliver an official oral presentation at this year’s American Society of Clinical Oncology annual meeting next month, becoming the first Korean company to do so regarding clinical studies of a cell therapy. The company said the study's principal researcher, Dr. Jeon Young-woo, will lead the presentation of the results from its Phase 2 clinical study of VT-EBV-N during the 2026 ASCO annual meeting slated from May 29 to June 2 in Chicago. VT-EBV-N is an Epstein-Barr

By The Korea Herald